Lord, Abbett & Co
VKTX icon

Lord, Abbett & Co’s Viking Therapeutics VKTX Stock Holding History

Lord, Abbett & Co’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-349,074
Closed -$28.6M – 597
2024
Q1 		$28.6M Buy
+349,074
New +$15.5M 0.09% 268
2023
Q3 		– Sell
-242,711
Closed -$3.94M – 590
2023
Q2 		$3.94M Sell
242,711
-90,823
-27% -$1.9M 0.01% 501
2023
Q1 		$5.55M Buy
+333,534
New +$3.45M 0.02% 469

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Lord, Abbett & Co's VKTX Position: Q2 2024 in Review

Lord, Abbett & Co sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 349,074 shares — an estimated $28.6M sold.

Lord, Abbett & Co first reported a position in VKTX in Q1 2023 and held it in 3 quarters. The position peaked at $28.6M in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Lord, Abbett & Co reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lord, Abbett & Co sold 349,074 Viking Therapeutics shares in Q2 2024, an estimated $28.6M.
  • Lord, Abbett & Co first reported a position in Viking Therapeutics in Q1 2023 and held it in 3 quarters.
  • Lord, Abbett & Co's Viking Therapeutics position peaked at $28.6M in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Lord, Abbett & Co's 13F filing for Q2 2024, filed 14 Aug 2024.